External Body Pressure in Heart Failure With Preserved Ejection Fraction

August 18, 2026 updated by: Duke University

External Body Pressure and the Impact on Exercise in Heart Failure With Preserved Ejection

The primary objective of the study is to test the impact of positive and negative body pressure on exercise capacity, symptoms, blood volume distribution and central cardiac hemodynamics in patients with heart failure and preserved ejection fraction. Aim 1 will study healthy volunteers and heart failure patients non invasively while Aim 2 will study heart failure patients invasively (intracardiac pressures).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
27

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Duke University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

30 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

  • Heart Failure Study Population

  • Inclusion Criteria (Aim 1 and 2):

    • Age greater than or equal to 30 yrs
    • Established diagnosis of HFpEF with left ventricular ejection fraction greater than or equal to 50%
    • NYHA II-III symptoms
    • Stable HF drug regimen for the preceding 1 month
    • Wedge pressure greater than or equal to 15 mmHg at rest or greater than or equal to 25 mmHg with peak exercise
    • (For Aim 2 only) Scheduled for an elective right heart catheterization at Duke University Hospital.

  • Exclusion Criteria (Aim 1 and 2):

    • HF hospitalization for type I myocardial infarction within 3 months
    • Infiltrative (ie amyloid) or hypertrophic cardiomyopathy
    • Uncontrolled atrial or ventricular arrhythmia
    • Chronic oxygen use
    • History of vasovagal syncope
    • Considered inappropriate to participate by PI or Sub-I
    • Healthy Volunteers (Controls)

  • Inclusion Criteria (Aim 1):

    • Age greater than or equal to 30 yrs
    • Able to speak English
    • Ambulatory [assistive devices ok]
    • Able to provide informed consent

  • Exclusion Criteria (Aim 1):

    • Acute myocardial infarction (3-5 days)
    • Unstable angina
    • Uncontrolled arrhythmia causing symptoms or haemodynamic compromise
    • Syncope
    • Active endocarditis
    • Acute myocarditis or pericarditis
    • Symptomatic severe aortic aneurysm
    • Uncontrolled asthma
    • Arterial desaturation at rest on room air <85%
    • Untreated left main stem coronary stenosis
    • Asymptomatic severe aortic stenosis
    • Severe untreated arterial hypertension at rest (>200 mm Hg systolic, >120 mm Hg diastolic)
    • Tachyarrhythmias or bradyarrhythmias
    • Hypertrophic cardiomyopathy
    • Significant pulmonary hypertension
    • Thrombosis of the lower extremity until treated for a minimum of 2 weeks
    • Within 2 weeks of acute symptomatic pulmonary embolus
    • Abdominal aortic aneurysm >8.0 cm
    • Electrolyte abnormalities
    • Pregnancy
    • Inmate of correctional facility (i.e. prisoner)
    • Diagnosed history of dementia
    • Inability to ambulate independently
    • Considered inappropriate to participate by Principal Investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental: Patients with heart failure (Aim 1)
Diagnostic test: Positive or negative pressure
Positive or negative pressure is applied via a closed chamber.
Active Comparator: Control: Healthy Volunteers (Aim 1)
Diagnostic test: Positive or negative pressure
Positive or negative pressure is applied via a closed chamber.
Experimental: Experimental: Patients with heart failure (Aim 2)
Diagnostic test: Positive or negative pressure
Positive or negative pressure is applied via a closed chamber.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Oxygen (O2) Consumption From Rest to 20 Watts Exercise
Time Frame: Day 1
A positive value indicates greater O2 consumption.
Day 1
Change in Cardiac Output From Rest to 0 Watts Exercise
Time Frame: Day 1
Day 1

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Cardiac Output From Rest to 20 Watts Exercise
Time Frame: Day 1
Day 1
Change in Heart Rate From Rest to 0 Watts Exercise
Time Frame: Day 1
A positive value indicates and increase in heart rate.
Day 1
Change in Heart Rate From Rest to 20 Watts Exercise
Time Frame: Day 1
A positive value indicates an increase in heart rate.
Day 1
Change in Respiration From Rest to 20 Watts Exercise
Time Frame: Day 1
A positive value indicates an increase in respiration.
Day 1
Change in O2 Consumption From Rest to 0 Watts Exercise
Time Frame: Day 1
A positive value indicates an increase in oxygen consumption.
Day 1
Change in O2 Consumption From Rest to 20 Watts
Time Frame: Day 1
A positive value indicates an increase in oxygen consumption.
Day 1
Change in Wedge Pressure From Rest to 20 Watts
Time Frame: Day 1
Day 1
Change in Symptom Burden From Rest to 20 Watts
Time Frame: Day 1
Day 1

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Symptom burden
Time Frame: Day 1
from rest to peak exertion we will assess symptom burden with dyspnea scales
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Duke University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Hemming, Duke

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 21, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 31, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 25, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 28, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 10, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 18, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Pro00112081

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings